Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle

H. Kume, S. Imbe, T. Iwanaga, Y. Tohda (Osakasayama, Japan)

Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Session: The best of pharmacology treatment for asthma and COPD
Session type: Poster Discussion
Number: 4835
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Kume, S. Imbe, T. Iwanaga, Y. Tohda (Osakasayama, Japan). Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle. Eur Respir J 2012; 40: Suppl. 56, 4835

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016

Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015


A comparison of beta2-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Potentiation effect of insulin on M3 muscarinic receptor agonist induced airway smooth muscle contraction
Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets
Year: 2019

Synergistic effects by combination of tiotropium with olodaterol result from cross talk between muscarinic and β2-adrenergic receptors via allosteric modulation
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016


Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta2-adrenoceptor agonists in airway smooth muscle
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013


Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009


The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC)
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011



Effects of fluticasone and salmeterol on cytokine-induced airway smooth muscle IP10 release
Source: Eur Respir J 2005; 26: Suppl. 49, 712s
Year: 2005

Impairment of β2-adrenoceptor agonist relaxation by cytokines is prevented by concomitant glucocorticoid treatment for formoterol but not for salmeterol in mouse trachea
Source: Eur Respir J 2007; 30: Suppl. 51, 714s
Year: 2007

Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013

Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013

Glycopyrrolate exerts medium-duration bronchodilator activity in guinea-pig and human airways
Source: Eur Respir J 2005; 26: Suppl. 49, 216s
Year: 2005

Effect of olodaterol on the relaxation of small airways
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011

Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017




Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi
Source: Eur Respir J 2007; 29: 575-581
Year: 2007



Central role of AC6 in β2 agonist induced relaxation of human airway smooth muscle
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016


Prostacyclin IP receptor activation blocks hyperosmolar-induced bronchoconstriction in isolated human small airways
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016